손발톱진균증 치료 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the onychomycosis treatment market size was valued at USD 3.51 billion in 2025 and estimated to grow from USD 3.66 billion in 2026 to reach USD 4.49 billion by 2031, at a CAGR of 4.19% during the forecast period (2026-2031).

This report is Segmented by Treatment Type (Device-Based Treatments, Medication-Based Treatment Including Allylamines, Azoles, Other Classes), Pathogen Type (Dermatophytes, Non-Dermatophyte Molds, Yeasts), Disease Type (Distal Subungual, White Superficial, and More), and Geography (North America, South America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Onychomycosis Treatment Market Trends and Insights

Rising Prevalence of Diabetes & Aging Population

Older adults and people living with diabetes drive a substantial proportion of new onychomycosis diagnoses, creating a self-reinforcing base for the onychomycosis treatment market. Diabetic patients show a 4.7-fold higher infection risk, and neuropathy often delays self-detection, allowing fungi to penetrate deeper nail structures. Countries such as Singapore illustrate the challenge; nearly one-third of type 2 diabetics report at least one complication, with neuropathy present in 13.3% of cases. Limited podiatry services in parts of the Pacific Islands highlight untapped volume opportunities where clinical need exceeds supply. Urbanization across Asia-Pacific accelerates lifestyle diseases and simultaneously increases disposable income, producing a sustained demand curve for both prescription drugs and premium in-clinic procedures.

Greater Adoption of Laser-Based Devices in Podiatry Clinics

Clinicians increasingly integrate Nd:YAG and diode laser platforms to meet patient demand for non-systemic solutions that circumvent hepatic monitoring requirements. Although cure-rate evidence remains heterogeneous, cosmetic nail improvement proves attractive in cash-pay settings concentrated in affluent urban markets. Prototype diode systems combined with photodynamic therapy have demonstrated complete clearance in small studies, bolstering professional confidence. Portable home-use lasers such as Welnax BioClear democratize access and lower treatment-episode costs, an innovation expected to boost device revenues within the onychomycosis treatment market. Clinics also bundle lasers into diabetic foot-care packages, improving safety profiles for patients on complex drug regimens.

High Recurrence & Treatment Failure Rates

Long treatment courses and moderate cure probabilities dampen patient persistence and raise relapse likelihood. Twenty-four-month efinaconazole studies delivered only 22.6% effective cure, underscoring the challenge of achieving both mycological and clinical clearance. Tropical climates sustain higher reinfection pressure, meaning practitioners must stress environmental interventions-shoe sterilization, humidity control, and periodic prophylactic applications-to prolong remission.

Other drivers and restraints analyzed in the detailed report include:

1. Expanding E-pharmacy Penetration in Emerging Markets
2. Launch of High-Penetration Nail Lacquers with Nanocarriers
3. Growing Azole & Allylamine Resistance Among Dermatophytes

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Medication products generated 85.02% of revenue in 2025. Allylamines remain the predominant class because they bind tightly to nail keratin and deliver fungicidal action over weeks. Azoles supply broader spectrum but rising resistance pushes physicians toward combination protocols, sometimes pairing oral terbinafine with topical efinaconazole for stubborn cases. The onychomycosis treatment market size for medications is forecast to expand steadily, yet its proportional slice could shrink as devices mature.

Device modalities, led by Nd:YAG and diode lasers, are on track for a 5.08% CAGR. Clinics pitch them to patients who cannot tolerate systemic therapy due to liver disease or drug interactions. Pilot trials suggest lasers speed visible clearing, a cosmetic win that resonates with image-conscious consumers. New platforms blend radiofrequency with ultrasound permeation, driving topical actives deeper. Manufacturers bundle post-procedure maintenance kits, ensuring recurring product sales within the onychomycosis treatment industry. Collaborations between device firms and pharmaceutical companies broaden distribution and align messaging.

Complete Report Scope:

• By Treatment Type
  • Device-based Treatments
  • Medication-Based Treatment
    • Allylamines
    • Azoles
    • Other Classes
• By Pathogen Type
  • Dermatophytes
  • Non-dermatophyte Molds
  • Yeasts
• By Disease Type
  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Total Dystrophic Onychomycosis
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America captured 42.41% of global revenue in 2025 thanks to broad insurance coverage and high clinic density. U.S. clinicians routinely blend systemic pills with in-office laser sessions, creating two revenue layers per patient. Canada's onychomycosis treatment market size stands at CAD 93.6 million (USD 68.9 million), buoyed by exclusive rights deals for novel lacquers. Mexico shows accelerating prescription volumes as diabetes clinics incorporate nail health modules into chronic-care bundles.

Asia-Pacific posts the fastest 5.71% CAGR. China and India host vast diabetic cohorts where even low therapy uptake translates into sizable demand. Japanese and South Korean hospitals adopt nanolacquers early, reflecting mature dermatology sectors. Inward medical tourism to Thailand and Malaysia adds incremental device procedures, elevating regional receipts for the onychomycosis treatment market. Government telemedicine schemes distribute specialist advice to remote provinces, shrinking urban-rural care gaps.

Europe remains a stable pillar. Harmonised CE marking speeds multi-country launches of innovative topicals. Sweden's Terclara seized 36% value share within its first month, proving European receptiveness to premium treatments. Southern Europe's humid coastline sustains high relapse rates, maintaining steady repeat-purchase cycles. Eastern European markets adopt generics aggressively, yet rising disposable income opens space for branded convenience formats.

1. Pfizer
2. Novartis
3. Bausch Health
4. Galderma
5. Johnson & Johnson
6. Bayer
7. GlaxoSmithKline
8. Sun Pharmaceuticals Industries
9. Cipla
10. Teva Pharmaceutical Industries
11. Kaken Pharmaceutical Co. Ltd.
12. Moberg Pharma
13. Taisho Pharmaceutical Co. Ltd.
14. Zeria Pharmaceutical Co. Ltd.
15. Hikma Pharmaceuticals
16. Cutera
17. Photocure ASA
18. Viamet Pharmaceuticals Holdings LLC
19. Medimetriks Pharmaceuticals
20. Merz Pharma

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising prevalence of diabetes & aging population
  • 4.2.2 Greater adoption of laser-based devices in podiatry clinics
  • 4.2.3 Expanding e-pharmacy penetration in emerging markets
  • 4.2.4 Launch of high-penetration nail lacquers with nanocarriers (2025+)
  • 4.2.5 FDA fast-track incentives for antifungal first-in-class molecules
  • 4.2.6 Inclusion of onychomycosis screening in corporate wellness plans
• 4.3 Market Restraints
  • 4.3.1 High recurrence & treatment failure rates
  • 4.3.2 Growing azole & allylamine resistance among dermatophytes
  • 4.3.3 Limited reimbursement for cosmetic-driven procedures
  • 4.3.4 Safety concerns over off-label systemic use in pediatrics
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD million)

• 5.1 By Treatment Type
  • 5.1.1 Device-based Treatments
  • 5.1.2 Medication-Based Treatment
    • 5.1.2.1 Allylamines
    • 5.1.2.2 Azoles
    • 5.1.2.3 Other Classes
• 5.2 By Pathogen Type
  • 5.2.1 Dermatophytes
  • 5.2.2 Non-dermatophyte Molds
  • 5.2.3 Yeasts
• 5.3 By Disease Type
  • 5.3.1 Distal Subungual Onychomycosis
  • 5.3.2 White Superficial Onychomycosis
  • 5.3.3 Proximal Subungual Onychomycosis
  • 5.3.4 Total Dystrophic Onychomycosis
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 South America
    • 5.4.2.1 Brazil
    • 5.4.2.2 Argentina
    • 5.4.2.3 Rest of South America
  • 5.4.3 Europe
    • 5.4.3.1 Germany
    • 5.4.3.2 United Kingdom
    • 5.4.3.3 France
    • 5.4.3.4 Italy
    • 5.4.3.5 Spain
    • 5.4.3.6 Rest of Europe
  • 5.4.4 Asia-Pacific
    • 5.4.4.1 China
    • 5.4.4.2 Japan
    • 5.4.4.3 India
    • 5.4.4.4 South Korea
    • 5.4.4.5 Australia
    • 5.4.4.6 Rest of Asia-Pacific
  • 5.4.5 Middle East and Africa
    • 5.4.5.1 GCC
    • 5.4.5.2 South Africa
    • 5.4.5.3 Rest of Middle East and Africa

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Pfizer Inc.
  • 6.3.2 Novartis AG
  • 6.3.3 Bausch Health Companies Inc.
  • 6.3.4 Galderma SA
  • 6.3.5 Johnson & Johnson Services Inc.
  • 6.3.6 Bayer AG
  • 6.3.7 GlaxoSmithKline plc
  • 6.3.8 Sun Pharmaceutical Industries Ltd.
  • 6.3.9 Cipla Ltd.
  • 6.3.10 Teva Pharmaceutical Industries Ltd.
  • 6.3.11 Kaken Pharmaceutical Co. Ltd.
  • 6.3.12 Moberg Pharma AB
  • 6.3.13 Taisho Pharmaceutical Co. Ltd.
  • 6.3.14 Zeria Pharmaceutical Co. Ltd.
  • 6.3.15 Hikma Pharmaceuticals plc
  • 6.3.16 Cutera Inc.
  • 6.3.17 Photocure ASA
  • 6.3.18 Viamet Pharmaceuticals Holdings LLC
  • 6.3.19 Medimetriks Pharmaceuticals Inc.
  • 6.3.20 Merz Pharma GmbH & Co. KGaA

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment